A Flow Cytometry-Based Assay for Quantifying Non-Plaque Forming Strains of Yellow Fever Virus

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Hammarlund, Erika ^a   Amanna, Ian J ^b   Dubois, Melissa E ^b   Barron, Alex ^a,c   Engelmann, Flora ^a,c   Messaoudi, Ilhem ^a,c   Slifka, Mark K ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Najit Technologies Inc   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3A8.B6; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DILUTION; EXPERIMENTAL INFECTION; FEMALE; FLOW CYTOMETRY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SENSITIVITY ANALYSIS; STAINING; SUPERNATANT; TISSUE CULTURE LIMITING DILUTION ASSAY; VIRUS CELL INTERACTION; VIRUS CONCENTRATION; VIRUS EXAMINATION; VIRUS LOAD; VIRUS PLAQUE; VIRUS STRAIN; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

AEDES; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; FEMALE; FLOW CYTOMETRY; MACACA MULATTA; MALE; MICE; VIRAL LOAD; VIRAL PLAQUE ASSAY; YELLOW FEVER VIRUS;

MACACA MULATTA; YELLOW FEVER VIRUS;

EID: 84866556888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041707     Document Type: Article

References (25)

1. Tomori O, (2004) Yellow fever: the recurring plague. Crit Rev Clin Lab Sci 41: 391-427.
2. Patterson KD, (1992) Yellow fever epidemics and mortality in the United States, 1693-1905. Soc Sci Med 34: 855-865.
3. Staples JE, Monath TP, (2008) Yellow fever: 100 years of discovery. JAMA 300: 960-962.
4. Gubler DJ, (2004) The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis 27: 319-330.
5. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J, (1998) Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159-167.
6. Li J, Hu DM, Ding XX, Chen Y, Pan YX, et al. (2011) Enzyme-linked immunosorbent assay-format tissue culture infectious dose-50 test for titrating dengue virus. PLoS One 6: e22553.
7. Monath TP, Cetron MS, Teuwen DE (2008) Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines, 5th ed. Philadelphia, PA: Saunders/Elsevier. 1748 p.
8. Tesh RB, Guzman H, da Rosa AP, Vasconcelos PF, Dias LB, et al. (2001) Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 183: 1431-1436.
9. Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, et al. (2010) Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28: 3827-3840.
10. Bae HG, Nitsche A, Teichmann A, Biel SS, Niedrig M, (2003) Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. J Virol Methods 110: 185-191.
11. Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, et al. (2008) Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 151: 40-46.
12. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
13. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11: 522-530.
14. Amanna IJ, Raue HP, Slifka MK, (2012) Development of a novel H2O2-based vaccine platform. Nature Medicine 18 (6):: 974-979.
15. Eldadah ZA, Asher DM, Godec MS, Pomeroy KL, Goldfarb LG, et al. (1991) Detection of flaviviruses by reverse-transcriptase polymerase chain reaction. J Med Virol 33: 260-267.
16. Miller RG, Teh HS, Harley E, Phillips RA, (1977) Quantitative studies of the activation of cytotoxic lymphocyte precursor cells. Immunol Rev 35: 38-58.
17. Taswell C, MacDonald HR, Cerottini JC, (1979) Limiting dilution analysis of alloantigen-reactive T lymphocytes. II. Effect of cortisone and cyclophosphamide on cytolytic T lymphocyte precursor frequencies in the thymus. Thymus 1: 119-131.
18. Slifka MK, Ahmed R, (1996) Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. J Immunol Methods 199: 37-46.
19. Amanna IJ, Slifka MK, (2006) Quantitation of rare memory B cell populations by two independent and complementary approaches. J Immunol Methods 317: 175-185.
20. Tesh RB, (1979) A method for the isolation and identification of dengue viruses, using mosquito cell cultures. Am J Trop Med Hyg 28: 1053-1059.
21. Kraus AA, Messer W, Haymore LB, de Silva AM, (2007) Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45: 3777-3780.
22. Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, et al. (2006) A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346: 53-65.
23. Liu J, Liu B, Cao Z, Inoue S, Morita K, et al. (2008) Characterization and application of monoclonal antibodies specific to West Nile virus envelope protein. J Virol Methods 154: 20-26.
24. Taswell C, (1981) Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 126: 1614-1619.
25. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJD, Zajac AJ, et al. (1998) Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection. Immunity 8: 177-187.